ANIXA Biosciences Inc Logo
US03528H1095
A2N6ZF
ANIX

ANIXA Biosciences Inc

Loading quotes...

Forecast

The analysts' average price target is €5.45 (+127.08%). The median is €5.45 (+127.08%).

Buy
  6
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Anixa Biosciences: two clinical cancer programs show encouraging early data

    At the H.C. Wainwright conference, Anixa Biosciences presented positive early data for its CAR‑T program in ovarian cancer (14 patients treated; one survived 28 months, several >1 year vs expected ~12 weeks) and for a breast cancer vaccine that completed phase I with 35 patients and showed immune responses in ~75%. The company has $14M in cash, an annual burn rate of $5–7M, is debt‑free, and plans to out‑license both programs to partners after clinical success rather than build a large commercial infrastructure. Next clinical steps are dose escalation for the CAR‑T and moving the vaccine into phase II with a randomized neoadjuvant design. » More on de.investing.com


  • Anixa has treated first patient in fifth cohort with highest CAR‑T dose in ovarian cancer

    Anixa has treated the first patient in the fifth cohort of its Phase 1 study at Moffitt Cancer Center with 1×10^7 CAR‑positive cells/kg, the highest dose level tested to date. No dose‑limiting toxicities were observed at the previous dose level (3×10^6/kg). The Lira‑Cel therapy targets the follicle‑stimulating hormone receptor and has shown long‑term survival of up to more than two years in some patients. The stock recently rose 14.7% to $3.27, with a market capitalization of $111 million. » More on de.investing.com


  • Anixa secures patent for breast cancer vaccine in South Korea

    The Korean Intellectual Property Office granted Anixa the patent (No. 10-2960889) for its breast cancer vaccine technology, providing protection in South Korea until 2040. The technology, exclusively licensed from the Cleveland Clinic, aims at prevention and treatment by immunization against human α-Lactalbumin. A phase‑1 study met all primary endpoints, was safe, well tolerated and showed an immune response in 74% of participants. Anixa remains clinically unbalanced but has more liquid assets than debt; analysts see price targets of $7–14 versus the current level of about $2.79. » More on de.investing.com


  • Anixa Biosciences receives patent in Mexico for breast cancer vaccine

    The Mexican Institute of Industrial Property has granted Anixa Biosciences a patent (No. 432748) covering key aspects of its breast cancer vaccine targeting α-lactalbumin, protecting the technology in Mexico until 2040. The vaccine, licensed exclusively from the Cleveland Clinic, met primary endpoints in a phase‑1 trial, showed good tolerability and elicited immune responses in 74% of participants; a phase‑2 study is being prepared. According to its balance sheet, Anixa has more cash than debt and strong short-term liquidity; analysts set price targets between $9 and $14 versus a current share price of $3.01. » More on de.investing.com


  • Anixa presents phase‑1 data on CAR‑T therapy Lira‑Cel at ISCT meeting

    Anixa announced that a presentation on the ovarian cancer therapy Lira‑Cel will be given at the annual meeting of the International Society for Cell & Gene Therapy. Cheryl Cox from the Moffitt Cancer Center will report on the study design, objectives and the current status of the ongoing phase‑1 trial (NCT05316129) in patients with recurrent ovarian cancer after at least two prior therapies. Lira‑Cel is an FSHR‑targeting CAR‑T/CER‑T therapy being developed in collaboration with the Moffitt Cancer Center; Anixa remains in the clinical stage, is not profitable, has more cash than debt, and has analyst price targets between $9 and $14. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2022, ANIXA Biosciences Inc has already paid €0.14 in dividends. The last payout was in July 2022.

Financials

In the last quarter, ANIXA Biosciences Inc had revenue of €0 and net profit of -€2.26m
(EUR) July 2026
YoY
Revenue 0 -
Gross profit -8.67k -
Net profit -2.26m 14.28%
EBITDA -2.36m 18.90%

Fundamentals

Metric Value
Market capitalization
€82.77m
Number of shares
34.76m
52-week high/low
€4.96 - €2.11
Dividends No
Beta
0.60
P/E ratio
-8.59
PEG ratio
0.01
P/B ratio
6.19
P/S ratio
0.00

Company profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Name
ANIXA Biosciences Inc
CEO
Amit Kumar
Headquarters San Jose, ca
USA
Website
Sector
Health Care
Industry
Biotechnology
IPO
07/10/1983
Employees 4

Ticker symbols

Exchange Symbol
NASDAQ
ANIX
Frankfurt
CY71.F
Düsseldorf
A2N6ZF.DU
München
A2N6ZF.MU
🍪

Parqet  uses cookies. Learn more